信立泰：关于JK06境外临床试验进展的公告

Core Viewpoint - The announcement from the company highlights promising preliminary results from the clinical trial of JK06, indicating good safety and efficacy in patients with advanced or metastatic tumors, including non-small cell lung cancer and breast cancer [2] Group 1 - The company, Xinlitai, received notification from its subsidiary, Salubris Biotherapeutics, Inc., regarding the presentation of partial dose escalation data for JK06 at the 2025 European Society for Medical Oncology (ESMO) annual meeting [2] - The preliminary data suggests that JK06 shows good safety and efficacy in patients with unresectable locally advanced or metastatic tumors [2]